Free Guide to Understanding Psoriasis Clinical Trials

What You Should Know About Psoriasis Clinical Trials

Clinical trials are research studies that test new treatments, medications, or therapies on human volunteers. For psoriasis, these trials investigate everything from new topical creams and biologic drugs to light therapy techniques and combination treatments. Understanding how these trials work can help you learn whether participating might be an option worth considering.

A clinical trial follows strict rules and protocols designed to protect participants and produce reliable scientific results. Researchers carefully monitor participants throughout the study, collecting data on how the treatment works and what side effects might occur. The U.S. Food and Drug Administration (FDA) requires companies to conduct clinical trials before approving new psoriasis treatments for public use.

Psoriasis affects approximately 3.1% of the U.S. population—about 7.5 million people—according to the National Psoriasis Foundation. Because psoriasis varies so much from person to person, researchers continually study new approaches. Some trials focus on mild plaque psoriasis, while others study severe cases or rare forms like pustular or erythrodermic psoriasis. Clinical trials have led to the development of biologic medications that have significantly improved treatment options over the past two decades.

Before considering participation, it helps to know that clinical trials operate in phases, each with different goals and participant numbers. Phase 1 trials typically involve 20 to 100 participants and test safety and dosage. Phase 2 trials include 100 to 500 participants and evaluate how well the treatment works. Phase 3 trials involve 1,000 to 5,000 participants and compare the new treatment to standard treatments. Phase 4 trials occur after FDA approval and continue monitoring long-term effects.

Practical takeaway: Learning the basic structure of clinical trials helps you understand what researchers are testing and why different trials may require different types of participants with different disease presentations.

The Different Phases of Psoriasis Clinical Trials

Each phase of a clinical trial has a specific purpose and involves different numbers of people. Understanding these phases helps explain why some trials are larger than others and what researchers hope to learn at each stage.

Phase 1 trials represent the earliest stage of human testing. These studies typically include a small group of healthy volunteers or people with the condition being studied. For psoriasis, Phase 1 trials might involve 20 to 100 participants and focus on determining whether a new medication is safe, what the appropriate dose should be, and what side effects might occur. Researchers carefully monitor participants for any negative reactions. Because Phase 1 trials are primarily about safety rather than effectiveness, participants may or may not experience improvement in their psoriasis symptoms during these studies.

Phase 2 trials expand to a larger group, usually 100 to 500 participants who have the condition being studied. For psoriasis trials, this means participants have confirmed psoriasis diagnoses. Phase 2 trials focus on whether the treatment actually works to reduce symptoms and continues to monitor for side effects. Researchers collect more detailed information about effectiveness and begin to understand which participants respond best to the treatment. This phase typically lasts several months to over a year.

Phase 3 trials involve the largest number of participants—often 1,000 to 5,000 people—and typically last one to four years. These trials compare the new treatment to either a placebo (inactive substance) or the current standard treatment. For psoriasis, this might mean comparing a new biologic medication to an existing biologic or topical treatment. Phase 3 data helps researchers understand how the new treatment compares to what doctors currently prescribe. The FDA uses Phase 3 results to make decisions about approving new treatments.

Phase 4 trials, also called post-market surveillance studies, begin after the FDA approves a treatment for public use. These ongoing studies continue to monitor the long-term effects and safety of the medication in larger populations. For psoriasis treatments, Phase 4 trials might track patients over five to ten years to understand how well the medication works over time and whether any new side effects emerge.

Practical takeaway: Knowing which phase a trial is in helps you understand what data researchers are collecting and what kind of medical monitoring you might expect during participation.

Types of Psoriasis Treatments Being Studied in Clinical Trials

Researchers are currently investigating many different approaches to treating psoriasis. These range from new applications of existing medication types to completely novel approaches based on emerging scientific understanding of how psoriasis develops.

Biologic medications represent one of the most active areas of psoriasis clinical research. These drugs are made from living cells and target specific parts of the immune system involved in psoriasis. Current biologic drugs on the market include TNF-alpha inhibitors, IL-17 inhibitors, and IL-23 inhibitors. Clinical trials continue to study newer biologic medications and combinations of biologics. For example, researchers are studying how combining two different biologic mechanisms might work better than either drug alone. Some trials investigate whether lower doses of biologics might be effective, potentially reducing side effects and costs.

Oral medications (pills and tablets) are another major focus of clinical research. Oral treatments offer convenience compared to injections or infusions, which appeals to both patients and researchers. Several oral medications targeting immune system pathways are currently in clinical trials for psoriasis. These include JAK inhibitors and other small-molecule drugs that can be taken by mouth. Researchers are studying their effectiveness for different types of psoriasis and determining the best dosing schedules.

Topical treatments—creams, ointments, and solutions applied directly to the skin—continue to be studied as well. Clinical trials are investigating new formulations that penetrate the skin more effectively, combine multiple active ingredients, or work through novel mechanisms. Some trials study topical treatments combined with other therapies to see if combination approaches produce better results than single treatments alone.

Light therapy (phototherapy) research includes studies of different wavelengths and treatment schedules. Narrowband ultraviolet B (NB-UVB) therapy remains a standard treatment, but researchers study how it compares to other light-based approaches and how it works best when combined with medications.

Emerging areas of psoriasis research include microbiome studies, investigating how bacteria on the skin might influence psoriasis, and studies of gut health and its connection to skin disease. Some trials explore lifestyle interventions combined with medical treatments.

Practical takeaway: Psoriasis research spans many different treatment approaches, so clinical trials address different treatment preferences—whether you're interested in injections, oral medications, topical options, or light therapy.

Who Participates in Psoriasis Clinical Trials and What to Expect

Clinical trials require participants with specific characteristics that match the research questions being asked. Understanding typical participant requirements helps you learn what researchers are studying and what participation might involve.

Most psoriasis clinical trials require participants to have a confirmed diagnosis of psoriasis from a doctor. Many trials specify a particular type of psoriasis—such as plaque psoriasis (the most common form affecting 80-90% of people with psoriasis), palmoplantar psoriasis affecting palms and soles, or scalp psoriasis. Some trials focus specifically on moderate to severe psoriasis, while others study mild cases. A few trials investigate psoriasis in specific populations, such as pediatric patients or people with psoriatic arthritis (joint inflammation accompanying the skin condition).

Age requirements vary by trial. Most trials studying adults require participants to be 18 years or older, though some specify a minimum age of 21. Pediatric trials study children and teenagers, often starting at age 2 or 6 depending on the medication and condition severity. Some trials have upper age limits, though many welcome older adults. Pregnancy status matters significantly—many trials exclude pregnant people or those planning pregnancy because of unknown effects on a developing fetus.

Most trials require that participants not be using certain other treatments during the study period. This allows researchers to understand how the trial medication specifically affects psoriasis without interference from other treatments. A "washout period" may be required—a time when participants stop taking their current psoriasis medications before starting the trial medication. The length depends on which medications were being used and how long the body takes to eliminate them.

Participation typically involves regular clinic visits for examination, blood tests, and photographs of affected skin areas. Researchers use these measurements to track whether psoriasis is improving. Visit frequency varies—Phase 2 trials might require weekly visits initially, then monthly visits. Phase 3 trials often space visits